Focusing on IGF/IGF-1R signaling, in vitro treatment with EGCG reduced IGF-1 and the activated form of IGF-1R levels and increased IGFBP-3 in human hepatoma and colon cancer cells, indicating that EGCG exhibited inhibitory actions on the IGF/IGF-1R axis [81,82]. The gene discussed is IGF1; the disease is colonic neoplasm.